TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01810536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hi-flow nasal cannula
Description: Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Study: NCT03881215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-uterine balloon
Description: intra-uterine balloon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-uterine balloon
Description: intra-uterine balloon
Study: NCT04449263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: Subjects will be randomized to wear Lens A (test) for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens A
Description: Subjects will be randomized to wear Lens A (test) for 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: Subjects will be randomized to wear Lens B (control) for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lens B
Description: Subjects will be randomized to wear Lens B (control) for 2 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Lenses
Description: All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Habitual Lenses
Description: All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Lenses
Description: All Subjects will wear their habitual lenses for 2 weeks prior to randomization of test lens and control lens.
Study: NCT03956446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic therapy
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.

Intervention type: DRUG
Group type: OTHER
Intervention: Symptomatic therapy
Description: Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
Study: NCT04388254

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simufilam 100 mg oral tablet
Description: Simufilam 100 mg oral tablet for b.i.d. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam 100 mg oral tablet
Description: Simufilam 100 mg oral tablet for b.i.d. administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablets
Study: NCT00857688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismu-Jet
Description: Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
Study: NCT02181244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg, one a day, for breakfast
Description: One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg, one a day, for breakfast
Description: One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal, one cup a day
Description: Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal, one cup a day
Description: Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
Study: NCT01212341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NK cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic NK cells
Study: NCT00583076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
Study: NCT01234389

Intervention type: DEVICE
Group type: OTHER
Intervention: Electrochemical H. pylori detection method
Description: Determination of H. pylori infection.

Intervention type: DEVICE
Group type: OTHER
Intervention: Electrochemical H. pylori detection method
Description: Determination of H. pylori infection.

Intervention type: DEVICE
Group type: OTHER
Intervention: IHC
Description: Determination of H. pylori infection.

Intervention type: DEVICE
Group type: OTHER
Intervention: IHC
Description: Determination of H. pylori infection.

Intervention type: DEVICE
Group type: OTHER
Intervention: C13-urea breath test
Description: Determination of H. pylori infection.

Intervention type: DEVICE
Group type: OTHER
Intervention: C13-urea breath test
Description: Determination of H. pylori infection.

Intervention type: DEVICE
Group type: OTHER
Intervention: HUT
Description: Determination of H. pylori infection.

Intervention type: DEVICE
Group type: OTHER
Intervention: HUT
Description: Determination of H. pylori infection.
Study: NCT02596932

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Protocol for intrapartum glucose management
Description: Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level \> 100mg/dL or \< 60mg/dL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Protocol for intrapartum glucose management
Description: Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose \> 120 mg/dL or \< 60 mg/dL
Study: NCT02602210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCL 0.9%
Description: IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
Study: NCT01607255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo carmine
Description: 0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water (exchange) method
Description: Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: water (exchange) plus dye method
Description: Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: air method
Description: The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
Study: NCT02224001

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Flag Technique
Description: A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result.
Study: NCT03050385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Study: NCT04239612

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical exercise
Description: Regular physical exercise in groups. Circular training: both strength and fitness
Study: NCT01573052

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlordiazepoxide
Description: 25mg four times daily x 3 days then tapered over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 300mg four times daily x 3 days then tapered over 3 days
Study: NCT04066231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIPUN GMS
Description: Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin Lactobionate
Description: Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium.
Study: NCT02677519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Orally-administered extended release formulation of methylphenidate; once daily dosing
Study: NCT01333930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active O2
Description: oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Adelholzener Mineralwasser
Description: natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
Study: NCT04087850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Socially Accepting Inclusive Classrooms
Description: Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
Study: NCT03617224

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TSEBT
Description: The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSEBT and pembrolizumab
Description: Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
Study: NCT01415336

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin, Cyclophosphamide
Description: doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, Capecitabine
Description: doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
Study: NCT01646489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miravirsen sodium
Description: Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
Study: NCT02029898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride 0,9%
Study: NCT01576068

Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry
Description: Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
Study: NCT00858104

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Laser Ablation
Description: Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
Study: NCT01710319

Intervention type: OTHER
Intervention: blood draw
Description: a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.

Intervention type: OTHER
Intervention: blood draw
Description: a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.

Intervention type: OTHER
Intervention: blood draw
Description: a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.

Intervention type: OTHER
Intervention: blood draw
Description: a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
Study: NCT00233064

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized Palivizumab
Description: Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Palivizumab
Description: Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
Study: NCT03669783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment Vincristin
Description: 1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment Vincristin
Description: 1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment Actinomycin-D
Description: 1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment Doxorubicin
Description: 1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment Carboplatin
Description: 1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
Study: NCT02703337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT02014337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone and Eribulin in combination
Description: Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
Study: NCT04251403

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mucosal Irrigation
Description: Following routine endoscopic evaluation, investigators will utilize the ERBEJET 2 device (ERBE USA Inc), which is commercially available for the treatment of mucosal lesions, to sample cells from the mucosal surface of the stomach. The aspirate will be collected for cytologic/pathologic assessment.
Study: NCT01164709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nelfinavir mesylate
Description: p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
Study: NCT03028519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3
Study: NCT02479646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL-1401H

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Neulasta

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Neulasta
Study: NCT01880138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: watching animated cartoon before general anesthesia

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: not watching animated cartoon beofre general anaesthesia
Study: NCT03390283

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete online survey
Study: NCT03391921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine
Description: All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
Study: NCT01085006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Tranexamic acid in cases, normal saline in controls

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Tranexamic acid in cases, normal saline in controls
Study: NCT04562051

Intervention type: OTHER
Intervention: prophylaxis regimen
Description: All recipients were divided into two groups: stratified prophylaxis group based on donors' and recipients' characteristics and routine prophylaxis group based on clinical experience

Intervention type: OTHER
Intervention: prophylaxis regimen
Description: All recipients were divided into two groups: stratified prophylaxis group based on donors' and recipients' characteristics and routine prophylaxis group based on clinical experience